Download PDF
PPH 2005; 11(5): 268-274
DOI: 10.1055/s-2005-858584
Fallbeispiel

© Georg Thieme Verlag KG Stuttgart · New York

Zum optimalen Umgang mit Nebenwirkungen von Neuroleptika: Auswertung einer Klientenerfahrung

J. Sin, C. GambleDer Artikel erschien zuerst in der Zeitschrift „Journal of Psychiatric and Mental Health Nursing” 2003; 10: 147 - 153. Der Abdruck erfolgt mit freundlicher Genehmigung des Verlages Blackwell Science Ltd. Übersetzung aus dem Englischen: Susan Smeaton.
Further Information

Publication History

Publication Date:
13 October 2005 (online)

    Permissions and Reprints

Trotz der in letzter Zeit aufkommenden psychosozialen Interventionen und anderer Behandlungsmethoden bleibt die medikamentöse Behandlung mit Neuroleptika der Eckpfeiler bei schizophrenen Erkrankungen, da diese die Rückfallquote anerkanntermaßen wirksam reduzieren. Gleichzeitig erschweren aber die Nebenwirkungen das Einhalten des gemeinsam erarbeiteten Behandlungsplans durch die Patienten. Bis vor kurzem haben psychiatrische Pflegekräfte wenig zur konsequenten Dokumentation bzw. zum Umgang mit diesen Symptomen beigesteuert. Der vorliegende Bericht zeigt, wie das Einfließen von pharmakologischem Hintergrundwissen und praktischer Erfahrung die Abstimmung bei einem Klienten optimieren kann. Beschrieben wird Herrn M.s Erfahrung mit seinen Medikamenten und welche Rolle psychiatrische Pflegekräfte innerhalb des Medikamentenmanagements unter interdisziplinärer Herangehensweise einnehmen können: Einschätzen von Wirkungen, Erfassen von und den Umgang mit Nebenwirkungen.

Literatur

  • 1 Baguley I, Baguley C. Psychosocial interventions in the treatment of psychosis.  Mental Health Care. 1999;  21 334-337
    Search in Google Scholar
  • 2 Bebbington P E, Wilkins S, Jones P. et al . Life event and psychosis. Initial results from the Camberwell collaborative psychosis study.  British Journal of Psychiatry. 1993;  162 72-79
    Search in Google Scholar
  • 3 Bennett J, Done J, Harrison-Read P. et al .A rating scale/checklist for the assessment of the side-effects of antipsychotic drugs. Brooker C, White E Community Psychiatric Nursing: a Research Perspective. Vol. 3 London; Chapman & Hall 1995: 1-19
    Search in Google Scholar
  • 4 Bennett J, Done J, Hunt B. Assessing the side-effects of antipsychotic drugs: a survey of CPN practice.  Journal of Psychiatric and Mental Health Nursing. 1995;  2 177-182
    Search in Google Scholar
  • 5 Birchwood M, Tarrier N. Innovations in the Psychological Management of Schizophrenia: Assessment, Treatment and Services. Chichester; Wiley 1992
    Search in Google Scholar
  • 6 Buchanan R W. Clozapine: efficacy and safety.  Schizophrenia Bulletin. 1995;  21 579-593
    CrossrefSearch in Google Scholar
  • 7 Burnett S. A new lease on life.  Nursing Times. 1994;  90 (30) 57
    Search in Google Scholar
  • 8 Clozapine Study Group . The safety and efficacy of clozapine in severe treatment-resistant schizophrenic clients in the U.K.  British Journal of Psychiatry. 1993;  163 150-154
    Search in Google Scholar
  • 9 Clozaril-Novartis .Summary of Product Characteristics - UK Specific. Surrey; Novartis 1999
    Search in Google Scholar
  • 10 Corrigan P W, Liberman R P, Engel J D. From non-compliance to collaboration in the treatment of schizophrenia.  Hospital Community Psychiatry. 1990;  41 1203-1211
    Search in Google Scholar
  • 11 Day J C, Wood G, Dcwey M. et al . A self-rating scale for measuring neuroleptic side-effects.  British Journal of Psychiatry. 1995;  166 650-653
    CrossrefSearch in Google Scholar
  • 12 Dev V J, Krupp P. Adverse event profile and safety of clozapine.  Review of Contemporary Pharmacotherapy. 1995;  6 197-208
    Search in Google Scholar
  • 13 Finn S E, Bailey J M, Schultz R T. et al . Subjective utility ratings of neuroleptics in treating schizophrenia.  Psychological Medicine. 1990;  20 843-848
    CrossrefSearch in Google Scholar
  • 14 Fowler D, Garcty P, Kuipers E. Cognitive Behavioural Therapy for Psychosis. Chichester; Wiley 1995
    Search in Google Scholar
  • 15 Gardner B, Owen L, Thompson S. Compliance: the need for a fresh approach.  Mental Health Nursing. 1999;  19 18-22
    Search in Google Scholar
  • 16 Gray R. Medication Management Handout Pack. London; Institute of Psychiatry 1999
    Search in Google Scholar
  • 17 Howard A, Reveley A. Review of compliance in schizophrenia.  Schizophrenia Monitor. 2000;  10 1-3
    Search in Google Scholar
  • 18 Kane J M. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview.  British Journal of Psychiatry. 1992;  160 (Suppl 17) 41-45
    Search in Google Scholar
  • 19 Kane J, Honigfeld G, Singer J. et al . Clozapine for the treatment-resistant schizophrenic (a double-blind comparison with chlorpromazine).  Archives of General Psychiatry. 1988;  45 789-796
    Search in Google Scholar
  • 20 Kemp R, Hayward P, Applewhaite G. et al . Compliance therapy in psychotic clients: randomised controlled trial.  British Medical Journal. 1996;  312 345-349
    Search in Google Scholar
  • 21 King D. Seminars in Clinical Psychopharmacology. London; Royal College of Psychiatrists 1995
    Search in Google Scholar
  • 22 Krawiecka M, Goldberg D, Vaughn M. A standardised psychiatric assessment scale for rating chronic psychotic clients.  Acta Psychiatrica Scandinavica. 1977;  55 299-308
    Search in Google Scholar
  • 23 Lieberman J A, Safferman A Z. Clinical profile of clozapine: adverse reactions and agranulocytosis.  Psychiatry Quarterly. 1992;  62 51-70
    Search in Google Scholar
  • 24 Lieberman J A, Safferman A Z, Pollack S. et al . Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.  American Journal of Psychiatry. 1994;  151 1744-1752
    Search in Google Scholar
  • 25 Lindstrom L H. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 clients treated with clozapine for up to 13 years.  Acta Psychiatrica Scandinavica Supplementum. 1988;  77 524-529
    Search in Google Scholar
  • 26 Marland G. Partnerships encourage clients to comply with treatment.  Nursing Times. 1998;  94 58-59
    Search in Google Scholar
  • 27 Marland G, Sharkey V. Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of literature.  Journal of Advanced Nursing. 1999;  30 1255-1262
    CrossrefSearch in Google Scholar
  • 28 Meltzer H Y. The importance of scroronin-dopaminc interactions in the action of clozapine.  British Journal of Psychiatry. 1992;  160 (Suppl 17) 22-29
    Search in Google Scholar
  • 29 Meltzer H Y. Clozapine: is another view valid?.  American Journal of Psychiatry. 1995;  152 821-825
    Search in Google Scholar
  • 30 Meltzer H Y, Burnett D, Bastani B. et al . Effects oi six months of clozapine treatment on the quality of life of chronic schizophrenic clients.  Hospital Community Psychiatry. 1990;  41 892-897
    Search in Google Scholar
  • 31 National Schizophrenia Fellowship .National Schizophrenia Fellowship Fact Sheet I. 3rd ed. London; NSF 1996
    Search in Google Scholar
  • 32 Shiloh R, Zemishlany Z, Aizenberg M. et al . Sulpiride augmentation in people with schizophrenia partially responsive to clozapine (a double-blind, placebo-controlled study).  British Journal of Psychiatry. 1997;  171 569-573
    Search in Google Scholar
  • 33 Sin J. One step at a time: negative symptoms.  Mental Health Care. 2000;  A 97-101
    Search in Google Scholar
  • 34 Sullivan G, Wells K B, Leake B. Clinical factors associated with better quality of life in a seriously mentally ill population.  Hospital and Community Psychiatry. 1992;  43 794-799
    Search in Google Scholar
  • 35 Taylor D, Hardy S. Psychopharmacology. Thomas B, Hardy S, Cutting P Stuart and Sundeen’s Mental Health Nursing Principles and Practice St Louis; Mosby 1997
    Search in Google Scholar

Jacqueline Sin

Compass Place Battle Hospital, Oxford Road, Reading

Berkshire RG 30 1AG

Großbritannien